Luis Mendez Mulet
Infectious Disease · Miami, FLNPI 1740210632
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.1% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by AbbVie at 24.4% of the total. 2025 is the largest year on record at $124, 9.8 times the $13 reported in 2019. That places this record below the midpoint for infectious disease clinicians in FL, where the typical reported total is $652.
Across 9 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$53
- Shionogi Inc$52
- Aimmune Therapeutics, Inc.$45
- Melinta Therapeutics, LLC$27
- Boehringer Ingelheim$26
- Merck$13
Across 78 payments — averaging $13,335 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$344K
- Genentech, Inc.$210K
- Hoffmann-la Roche Limited$188K
- Merck$97K
- Sekisui Diagnostics LLC$96K
- Amgen$50K
- plus $55K from 2 others
What the payments were for
- Food & beverage$20394%
- Education$136%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 2 | $53 |
| Shionogi Inc | 2 | $52 |
| Aimmune Therapeutics, Inc. | 2 | $45 |
| Melinta Therapeutics, LLC | 1 | $27 |
| Boehringer Ingelheim | 1 | $26 |
| Merck | 1 | $13 |
How this compares
$215 in reported general payments places this provider in the 30th percentile of 669 infectious disease providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StribildElviteg/Cob/Emtri/Tenofo Disop | 12 | $58,082 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Miami
- Douglas BrustMiami$359K
- Dushyantha JayaweeraMiami$98K
- Ricardo FrancoMiami$96K
- Lilian AbboMiami$61K
- Jorge MurilloMiami$53K
- Thomas HootonMiami$42K
- Gilberto Torres-MadrizMiami$42K
- Vanessa SilebiMiami$32K
- Hector BolivarMiami$25K
- Jose Camargo GalvisMiami$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.